Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) on November 17, 2025 announced an underwritten public offering of shares of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of the shares sold. All shares are being offered by Invivyd and the offering is subject to market conditions; timing, size and terms are not assured.
The company said it intends to use net proceeds, together with existing cash, for commercial preparedness for VYD2311, continued R&D for RSV and measles programs, SPEAR Study Group efforts on monoclonal antibody effects for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and general corporate purposes.
Invivyd (NASDAQ: IVVD) reported Q3 2025 PEMGARDA net product revenue of $13.1M, up 41% YoY and 11% QoQ. The company ended Q3 with $85.0M cash and reported October 2025 ending cash of over $100M after raising proceeds from a $57.5M public offering and $29.8M ATM sales. Invivyd received FDA IND clearance and alignment for its REVOLUTION pivotal program for VYD2311, with two Phase 3 trials planned (DECLARATION, n=1,770; LIBERTY, n=210) and top-line data expected mid-2026. Q3 R&D expense fell to $8.0M from $57.9M a year earlier; SG&A was $15.0M. Net loss narrowed to $10.5M (Q3 2025).
Invivyd (Nasdaq: IVVD) will host a conference call on Thursday, November 6, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide a corporate update.
Interested parties may join the live webcast via the company's investor relations site and are advised to log in about 15 minutes before the start. A recording will be available on the investor relations website shortly after the event.
Invivyd (Nasdaq: IVVD) will host a live webcast on Thursday, October 30, 2025 at 8:30 a.m. ET to present an overview of the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody candidate to prevent COVID.
Key presenters include Marc Elia (Chairman), Tim Lee (Chief Commercial Officer), Robert Allen, PhD (Chief Scientific Officer), and Mark Wingertzahn, PhD (SVP, Clinical Development). Listeners should join the webcast link 15 minutes before start; a replay will be posted to the company investor relations website about two hours after the call ends.
Invivyd (NASDAQ: IVVD) announced U.S. FDA clearance of its IND and alignment on the REVOLUTION clinical program for VYD2311, a vaccine‑alternative monoclonal antibody to prevent COVID. The company plans two trials: DECLARATION (Phase 3, BLA‑enabling, ~2,000 participants; single IM dose and monthly dosing arms) and LIBERTY (active‑controlled safety/tolerability vs. mRNA vaccine, ~300 participants with co‑administration arm subject to final FDA alignment). Trials aim to start around year‑end 2025 with top‑line data anticipated mid‑2026. Invivyd says commercial launch quantities are available and trials are funded by a recent capital raise.
Invivyd (NASDAQ: IVVD) has appointed Dr. Paul B. Bolno to its Board of Directors and Compensation Committee. Dr. Bolno, who currently serves as President and CEO of Wave Life Sciences, brings extensive experience in pipeline development and technological platforms for creating new medical products.
The appointment comes as Invivyd focuses on developing solutions for viral infectious diseases, particularly in the areas of COVID-19 prevention and treatment. Dr. Bolno also serves on the Board of ExpressionEdits and chairs the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.
Invivyd (Nasdaq: IVVD) has appointed Kristie Kuhl as Chief Communications Officer to lead the company's communications and patient advocacy initiatives. Kuhl, recognized in PRWeek's 2024 Health Influencer 30, joins from Zeno Group where she served as Global Managing Director of Health & Wellness.
In her new role, Kuhl will focus on advancing understanding of Invivyd's work in developing monoclonal antibodies for viral disease prevention and treatment, while building stakeholder trust and supporting company growth. Her appointment comes at a strategic time as Invivyd aims to strengthen its scientific credibility and relationships with key healthcare stakeholders.
Invivyd (Nasdaq: IVVD) announced its participation in two upcoming investor conferences in New York. The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, 2025, at 2:10 PM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 12:00 PM ET.
The presentations will be available via live webcasts on the company's investor website and archived for approximately 30 days. Management will also host investor meetings during both conferences.
Invivyd (Nasdaq: IVVD) has successfully closed its public offering, raising $57.5 million in gross proceeds. The offering included 89.2 million shares of common stock at $0.52 per share and 21.3 million pre-funded warrants at $0.5199 each. The underwriter, Cantor, fully exercised its option to purchase an additional 14.4 million shares.
The financing was led by RA Capital Management and Janus Henderson Investors. Funds will support the VYD2311 clinical program, research in RSV and measles, and advancement of the SPEAR Study Group's efforts regarding Long COVID and COVID-19 Post-Vaccination Syndrome treatments.
Invivyd (Nasdaq: IVVD) has announced the pricing of a $50 million public offering, consisting of 74,811,404 shares of common stock at $0.52 per share and pre-funded warrants for 21,342,442 shares at $0.5199 per warrant.
The company has granted underwriters a 30-day option to purchase up to 14,423,076 additional shares. The offering, managed by Cantor as sole book-runner, is expected to close around August 22, 2025. Proceeds will fund the VYD2311 clinical program, research in RSV and measles, SPEAR Study Group efforts for Long COVID research, and general corporate purposes.